|Type of business||Private|
Type of site
|Patient network and real-time research platform|
|Headquarters||Cambridge, Massachusetts, United States|
|Key people||Ben Heywood
|Slogan(s)||"Live better, together"|
|Launched||October 10, 2005|
PatientsLikeMe is a patient network and real-time research platform. Through the network, patients connect with others who have the same disease or condition and track and share their own experiences. In the process, they generate data about the real-world nature of disease. With nearly 500,000 members, PatientsLikeMe is a trusted source for real-world disease information and a clinically robust resource that has published more than 80 research studies. PatientsLikeMe was inspired by the life experiences of Stephen Heywood, diagnosed in 1998 at the age of 29 with amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease. The company was founded in 2004 by his brothers Jamie and Ben Heywood and long-time family friend Jeff Cole.
- 1 History
- 2 Expansion Beyond ALS
- 3 Products and services
- 4 Scientific work
- 5 Corporate affairs and culture
- 6 Awards and Recognition
- 7 References
- 8 External links
After being diagnosed with ALS, Stephen's family founded a non-profit, ALS Therapy Development Institute, in an attempt to slow his disease and treat his symptoms. However, the slow pace of research and the trial-and-error approach was time-consuming and repetitive. They realized that Stephen’s experience was like that of other patients around the world who often have specific questions about their treatment options, and about what to expect. PatientsLikeMe helps patients connect with others who know firsthand what they are going through to share advice and resources. Through a health profile made up of structured and quantitative clinical reporting tools, members are able to monitor their health between doctor or hospital visits, document the severity of their symptoms, identify triggers, note how they are responding to new treatments, and track side effects. They have the opportunity to learn from the aggregated data of others with the same disease and see how they are doing in context with others. Members of the site use social tools such as forums, private messages, and profile comments to give and receive support from others, a support mechanism that has been shown to help improve their management and perceived control.
Expansion Beyond ALS
PatientsLikeMe launched its first online community for ALS patients in 2006. From there, the company began adding other communities for other life-changing conditions, including multiple sclerosis (MS), Parkinson's disease, fibromyalgia, HIV, chronic fatigue syndrome, mood disorders, epilepsy, organ transplantation, progressive supranuclear palsy, multiple system atrophy, and Devic's disease (neuromyelitis optica). The company's approach was to read the scientific literature and listen to patients to identify outcome measures, symptoms, and treatments that were important to patients and could be accurately reported. For example, the development of the MS community involved the development of a new patient reported outcome measure, the MS Rating Scale (MSRS), to ensure patients could accurately determine how their condition was progressing over time. However, building one community at a time was a slow process and the company risked being overly narrow in focus while excluding more than 5,000 patients who had requested new communities as of December 2010.
In April 2011, the company expanded its scope and opened its doors to any patient with any condition. Today the website covers more than 2,500 health conditions, with new members joining daily from the US and other countries around the world. Of note are the more than 9,000 ALS members, who have helped make PatientsLikeMe’s flagship community the largest online population of ALS patients in the world. In the United States, approximately 10 percent of newly diagnosed ALS patients register on the site each month, and 2 percent of all multiple sclerosis patients in the US participate in the community.
Products and services
Online data-sharing platform
PatientsLikeMe allows members to input real-world data on their conditions, treatment history, side effects, hospitalizations, symptoms, disease-specific functional scores, weight, mood, quality of life and more on an ongoing basis. The result is a detailed longitudinal record – organized into charts and graphs – that allows patients to gain insight and identify patterns. The data-sharing platform is designed to help patients answer the question: “Given my status, what is the best outcome I can hope to achieve, and how do I get there?”. Answers come in the form of shared longitudinal data from other patients with the same condition(s), thus allowing members to place their experiences in context and see what treatments have helped other patients like them. Some communities, such as ALS, feature visual aids such as percentile curves on the patient profile, so that an individual user can see whether their rate of progression is fast, slow, or about average. A seizure tracker for patients with epilepsy helps identify triggers such as missed medication doses, sleep deprivation, or alcohol use, and a "mood map" for patients with mood disorders helps to show different factors underlying their condition such as emotional control, anxiety, or external stress while all users can look for patterns in their daily health status such as day of the week or time of day.
Three studies have been published suggesting that use of the platform improves patient outcomes. A survey conducted in 2010 amongst patients with ALS, MS, Parkinson's disease, HIV, fibromyalgia, and mood disorders found that 72% of users had found the site helpful in learning about a symptom they had experienced, 57% for understanding the side effects of a treatment, 42% in helping them to find another patient like them, amongst others. A second study conducted in epilepsy found that in addition to the earlier benefits reported, patients with epilepsy reported a better understanding of their symptoms (59%), seizures (58%), and symptoms or treatments (55%). The number of benefits they reported from using the site was strongly associated with the number of social connections they made with other members, dubbed the "dose effect curve of friendship". Finally, a third study conducted with the US Department of Veteran Affairs and the University of California at San Francisco reported statistically significant improvements in validated measures of self-management and self-efficacy in veterans with epilepsy as a result of engaging with the site for a period of six weeks.
Clinical trial awareness
Just 3-5% of patients with serious health conditions such as cancer take part in clinical trials, due in part to a lack of awareness among patients. One of the first services PatientsLikeMe provided to its members and commercial partners was a "clinical trial awareness" service that allowed targeted messaging about trials for which patients might be eligible, based on their submitted profile data. Patients benefitted by getting accelerated access to clinical trials whereas pharmaceutical companies benefited by shortening their clinical trials by as much as a few months. However, this piecemeal approach only allowed for increased awareness of those trials which were being sponsored by commercial partners, so on June 9, 2011, PatientsLikeMe released a free tool which would show members a list of all the trials worldwide from ClinicalTrials.gov tailored to their condition and demographics.
Health Economics and Outcomes Research
One of the ways in which the site makes revenue is by conducting scientific research studies for pharmaceutical companies, typically with an emphasis on issues that are important to both patients and industry. For example, in 2011 a partnership with Novartis studied the barriers faced by people with multiple sclerosis in being adherent to taking their medication, which led to the development of an MS Treatment Adherence Questionnaire (MS-TAQ) which was made available to help patients and their doctors identify and address these issues through coping strategies and enhanced communication. A 2013 collaboration with UCB explored factors underlying quality of life in epilepsy and identified a number of issues beyond the occurrence of seizures as being important, including symptoms such as problems concentrating, depression, memory problems, and treatment side effects. Such research helps to improve understanding of disease, identify new approaches to management, and generate ideas to improve the products and services developed by pharmaceutical companies.
Open Research Exchange
Following the award in 2013  and 2014  of $4.5m in grants from the Robert Wood Johnson Foundation, the company developed an online tool called the Open Research Exchange (ORE) that allowed for the rapid creation, prototyping, testing, and validation of patient reported outcome measures, questionnaires that can establish the impact of symptoms and disease on patients. During the period of the grant, a number of academic collaborators were invited to develop measures on the platform including measures of treatment burden, hypertension management, feelings of satiety in diabetes and treatment burden in chronic illness. The tool offers researchers the ability to rapidly get input from large numbers of patients in a matter of weeks or months  as opposed to much slower forms of research which can take years to complete. A number of tools such as the Treatment Burden Questionnaire  and the Suicide Ideation and Behavior Assessment Tool (SIBAT) have been published in the scientific literature for use by researchers and an editorial co-authored with industry leaders and a researcher at the FDA outlined ways in which PROs developed on the ORE could be used for the development of new medicines. In addition to the traditional scientist-lead instruments, one instrument was developed by a person living with MS.
A key differentiator of the site from more traditional online support groups, message boards, social media sites and list-serves is the emphasis on structured quantitative data which can be aggregated and used for research purposes. This has permitted PatientsLikeMe's research team to author more than 80 peer-reviewed published scientific articles in collaboration with academic and commercial partners in leading journals such as the BMJ, Nature Biotechnology, and Neurology. In addition, PatientsLikeMe has been mentioned by others in more than 3,000 published articles in the scientific literature and has been featured as a business case study by the Harvard Business Review. The company has also invited researchers to become embedded with the company such as an in-depth study explaining the organization of the platform and highlighting some of the challenges that social media and patient-centred research models are facing.
Wherever possible, PatientsLikeMe has a policy of publishing its research output in open access form, so that patients, clinicians, and researchers can easily access their scientific output. Instruments and questionnaires developed on PatientsLikeMe such as the MS Rating Scale or MS Treatment Adherence Questionnaire are licensed under Creative Commons so that they can be used freely by the community without complex or costly licensing requirements. The company also provides patients that take part in its studies with "givebacks" which concisely and rapidly give them feedback in lay language as to the results of research in which they have participated so they can understand how donating their data has been useful for research.
The company's best known scientific endeavor relates to an online refutation of a clinical trial in ALS. In 2008, a small Italian study was published suggesting that lithium carbonate could slow the progression of ALS. In response, hundreds of members of PatientsLikeMe with the disease began taking the drug off-label. Using the self-reported data of 348 ALS patients and taking just nine months to complete, PatientsLikeMe conducted a study which demonstrated that lithium did not slow the progress of the disease. The team suggested that online collection of patient self-report data was no substitute for randomized placebo-controlled trials, but it might be a useful new form of clinical research in certain circumstances. A later study described how patients attempted to use the same tools to unblind clinical trials in which they were enrolled to try and see whether or not the experimental drugs they were taking were working.
Corporate affairs and culture
Describing itself “a not just for profit,” PatientsLikeMe does not allow advertising on its site but rather keeps the site free for users by selling research services as well as aggregated, de-identified data to its partners, including pharmaceutical companies and medical device makers. Typical commercial services include helping to optimize the designs of clinical trial protocols, developing new patient reported outcomes, or identifying the severity of symptoms in specific patient groups. The company enforces transparency about who uses the data and partners have included UCB, Novartis, Sanofi, Avanir Pharmaceuticals and Acorda Therapeutics.
Awards and Recognition
In 2007 the company was named as one of the "15 Companies that Will Change the World" by Business 2.0 and CNN Money as well as added to the list of "Top Health IT Innovators" by FierceHealthIT . In 2008 PatientsLikeMe received the Prix Ars Electronica Award of Distinction  and in March featured in a New York Time Magazine article entitled "Practicing Patients", by Thomas Goetz, who later went on to feature the site in his book "The Decision Tree". Later in 2008 a television segment with Sanjay Gupta aired on the CBS Evening News. Fast Company (magazine)'s 2010 list of Most Innovative Companies ranked PatientsLikeMe at #23. A May 2010 New York Times article entitled "When Patients Meet Online”, outlined the potential for advances for research. In 2012 Sanjay Gupta featured a research project conducted in collaboration with PatientsLikeMe on CNN's The Next List, profiling collaborator Dr Max Little. In January 2013, the company featured as a clue on Jeopardy! - "A health data-sharing platform, patientslikeme.com, was founded by 3 engineers from this Boston-area university, initially"; the correct answer, provided by Helen Juvonen, was MIT.
- Wicks P, Massagli M, Frost J, Brownstein C, Okun S, Vaughan T, Bradley R, Heywood J (2010). "Sharing health data for better outcomes on PatientsLikeMe.". J Med Internet Res. 12 (2): e19. doi:10.2196/jmir.1549. PMID 20542858.
- Marketwire, UCB and PatientsLikeMe Partner to Give People With Epilepsy a Voice in Advancing Research Jun 15, 2009 07:00 ET
- PatientsLikeMe Calls All Patients With Any Condition to Join
- ALS Community Overview on PatientsLikeMe
- AHRQ Health Care Innovations Exchange, Online Communities Foster Data-Sharing, Communication, and Learning Among Patients With Neurologic and Other Chronic Diseases Oct 17, 2012
- (http://www.ted.com/talks/jamie_heywood_the_big_idea_my_brother_inspired TED Talk: The Big Idea My Brother Inspired)
- "Can We Use Social Media to Support Content Validity of Patient-Reported Outcome Instruments in Medical Product Development?". Value in Health. 18: 1–4. doi:10.1016/j.jval.2014.10.001.
- Press release of new ClinicalTrials.Gov tool
- PatientsLikeMe Information for industry partners page on clinical trial awareness
- "Adaptation and validation of the Treatment Burden Questionnaire (TBQ) in English using an internet platform". BMC Medicine. 12: 109. doi:10.1186/1741-7015-12-109.
- http://www.patientslikeme.com/research/publications PatientsLikeMe's Publications
- Google Scholar search for PatientsLikeMe
- Tempini, Niccolò (2015). "Governing PatientsLikeMe: Information Production and Research Through an Open, Distributed, and Data-Based Social Media Network". The Information Society. 31 (2): 193–211. doi:10.1080/01972243.2015.998108.
- Kallinikos, Jannis; Tempini, Niccolò (2014). "Patient Data as Medical Facts: Social Media Practices as a Foundation for Medical Knowledge Creation". Information Systems Research. 25 (4): 817–833. doi:10.1287/isre.2014.0544.
- Fornai, F.; Longone, P.; Cafaro, L.; Kastsiuchenka, O.; Ferrucci, M.; Manca, M. L.; Lazzeri, G.; Spalloni, A.; et al. (2008). "Lithium delays progression of amyotrophic lateral sclerosis". Proceedings of the National Academy of Sciences. 105 (6): 2052–2057. doi:10.1073/pnas.0708022105.
- Brownstein CA, Brownstein JS, Williams DS, Wicks P, Heywood J (2009). "The power of social networking in medicine.". Nat Biotechnol. 27 (10): 888–890. doi:10.1038/nbt1009-888. PMID 19816437.
- Wicks P, Vaughan TE, Massagli MP, Heywood J (2011). "Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm". Nat Biotechnol. 29 (5): 411–414. doi:10.1038/nbt.1837. PMID 21516084.
- PatientsLikeMe Partners Page
- PatientsLikeMe : Press
- Goetz, Thomas (March 23, 2008). "Practicing Patients". The New York Times.
- Social Networking For Medical Patients - CBS Evening News with Katie Couric
- Fast Company's 2010 Most Innovative Companies
- When Patients Meet Online